Quva and CAPS collaborate to maintain supply of
critical medications to U.S. hospitals.
SUGAR LAND, Texas and ALLENTOWN, Pennsylvania — September 8th, 2026 — QuVa Pharma, Inc. (“Quva”) and Central Admixture Pharmacy Services, Inc. (“CAPS”) today announced that Quva has acquired a range of essential medications from CAPS following CAPS’ decision to exit the 503B sterile compounding business. Quva expects to begin introducing selected products from the acquired portfolio in phases later in 2026 and to expand its offerings over the following six (6) months.
“We are proud to work with Quva, a recognized leader in 503B outsourcing manufacturing, to help ensure continued access to a number of essential medications,” said Michael Parden, Chief Executive Officer of B. Braun of America. “Products such as Cardioplegia, Total Parenteral Nutrition and Heparin play an important role in patient care, and this transition supports continuity of supply for the patients and providers who depend on them. We also appreciate Quva’scommitment to providing employment opportunities for CAPS colleagues currently supporting our local 503B sterile compounding operations.”
Operating from more than 200,000 sq. ft. of FDA-registered 503B manufacturing facilities in New Jersey and Texas and 100,000 sq. ft. of forward distribution centers in Texas and Arizona, Quva serves more than 3,500 hospitals and health system customers nationwide with its broad portfolio of sterile compounded medications manufactured under rigorous quality standards.
“We appreciate the opportunity to partner with CAPS to maintain the supply of these critical medications,” said Stuart Hinchen, Chief Executive Officer of Quva. “Health systems depend on prepared medications that are essential to patient care but difficult to produce reliably at scale. This acquisition reflects our commitment to investing in the specialized products, manufacturing capabilities, quality systems, distribution infrastructure, technology, and people needed to support these critical medication categories. We look forward to working with CAPS and our health-system customers to maintain supply and build more dependable solutions for the future.”
About Quva
Quva helps health systems address critical medication needs across the enterprise. Through two distinct businesses, Quva supports both the supply of essential prepared medications and the use of complex medication data to improve enterprise decision-making.
Quva Pharma partners with hospitals and health systems to support categories of ready-to-administer and compounded medications that are essential to patient care and difficult to prepare reliably at scale.
Quva BrightStream connects and normalizes medication data from more than 400 source systems across sites of care, helping health-system leaders identify what matters, understand why, and make better decisions.
Together, Quva’s businesses share a commitment to helping health systems deliver safe, dependable, and effective medication care.
For more information, visit onequva.com.
About B. Braun
B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we’re uniquely positioned to help health systems succeed now and in the future. B. Braun is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. The company employs 8,500 people at over 30 locations across North America.
Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our website.
Quva Media Contact
Peter Jenkins
Peter.Jenkins@oneQuva.com
B. Braun Media Contact
Allison Longenhagen
Allison.Longenhagen@bbraunusa.com
(484) 523-9801
